PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
Phase Holographic Imaging (PHI) announces its participation in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024. This event offers a valuable platform for PHI to connect with fellow companies in the field and present the Company’s innovative offerings for regenerative medicine and cell therapy.
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024. As a pioneering force in medical technology, PHI specializes in developing advanced microscope-based research instruments that revolutionize the study of living cell cultures. PHI's non-invasive cell imaging and analysis method is considered one of the very few methods that have the potential to become standards for the quality, safety and democratization of future cell therapies.
PHI's CEO, Patrik Eschricht, will showcase the company’s latest advancements and detail how the company is uniquely positioned to contribute to the rapidly growing field of regenerative medicine and cell therapy research.
Date: February 14, 2024
Time: 09.10 AM
Watch live: https://www.redeye.se/events/966283/redeye-theme-cell-therapy
For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
Phase Holographic Imaging (PHI) develops instrumentation and software for time-lapse cytometry. The products are used for long-term quantitative analysis of the dynamics of live cells, particularly significant in the research of cancer, as well as in the treatment of inflammatory and autoimmune diseases. The products are sold globally through the company's distributors. The company is based in Lund, Sweden, and in Boston, Massachusetts.
